Theprubicin
Tyrosine Kinase Inhibitor
Xinrui Zhu，MDSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Tyrosine Kinase Inhibitor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
Icotinib Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
Adbelimumab Fujian Cancer Hospital | Phase 2 | CCC |
Befotertinib Peng Zhang | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Theprubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →